Li, W. F., Rockwell, B., Shan, X., Mantzaris, I., Shastri, A., Gritsman, K., Sica, R. A., Kornblum, N., Levitz, D., Shapiro, L., Gupta, R., Peeke, S., Munoz, A., Dhawan, A., Fehn, K., Comas, M., Verceles, J., Cooper, D., Konopleva, M., Feldman, E., Verma, A., Goldfinger, M. (2025). Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence. Blood. https://doi.org/10.1182/blood-2025-4429